Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Histochemistry and Cell Biology
|
June 10, 2016
Glu-tubulin is a marker for Schwann cells and can distinguish between schwannomas and neurofibromas
Josune García-Sanmartín, Susana Rubio-Mediavilla, José J Sola-Gallego, et al.
Frontiers in Physiology
|
January 10, 2018
Lack of Adrenomedullin Aggravates Acute TNBS-Induced Colitis Symptoms in Mice, Especially in Females
Sonia Martínez-Herrero, Ignacio M Larrayoz, Judit Narro-Íñiguez, et al.
Leukemia Research Reports
|
March 6, 2014
Intravascular large B cell lymphoma
Ricardo García-Muñoz, Susana Rubio-Mediavilla, Diego Robles-de-Castro, et al.
Scientific Reports
|
December 14, 2017
Small molecules related to adrenomedullin reduce tumor burden in a mouse model of colitis-associated colon cancer
Laura Ochoa-Callejero, Josune García-Sanmartín, Sonia Martínez-Herrero, et al.
Plos One
|
January 18, 2013
Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model
Laura Ochoa-Callejero, Laura Pérez-Martínez, Susana Rubio-Mediavilla, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
February 9, 2018
Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet
Laura Pérez-Martínez, Laura Ochoa-Callejero, Susana Rubio-Mediavilla, et al.
Cancers
|
March 13, 2024
Expression of Mitochondrial Long Non-Coding RNAs, MDL1 and MDL1AS, Are Good Prognostic and/or Diagnostic Biomarkers for Several Cancers, Including Colorectal Cancer
Pablo Garrido, Adrián Casas-Benito, Ignacio M Larrayoz, et al.
Plos One
|
January 10, 2024
Role of maraviroc and/or rapamycin in the liver of IL10 KO mice with frailty syndrome
Laura Pérez-Martínez, Lourdes Romero, Eva M Verdugo-Sivianes, et al.
Aging
|
May 1, 2020
Implications of maraviroc and/or rapamycin in a mouse model of fragility
Laura Pérez-Martínez, Lourdes Romero, Sandra Muñoz-Galván, et al.
The Journal of Antimicrobial Chemotherapy
|
March 22, 2014
Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)
Laura Pérez-Martínez, Patricia Pérez-Matute, Javier Aguilera-Lizarraga, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Histochemistry and Cell Biology
|
June 10, 2016
Glu-tubulin is a marker for Schwann cells and can distinguish between schwannomas and neurofibromas
Josune García-Sanmartín, Susana Rubio-Mediavilla, José J Sola-Gallego, et al.
Frontiers in Physiology
|
January 10, 2018
Lack of Adrenomedullin Aggravates Acute TNBS-Induced Colitis Symptoms in Mice, Especially in Females
Sonia Martínez-Herrero, Ignacio M Larrayoz, Judit Narro-Íñiguez, et al.
Leukemia Research Reports
|
March 6, 2014
Intravascular large B cell lymphoma
Ricardo García-Muñoz, Susana Rubio-Mediavilla, Diego Robles-de-Castro, et al.
Scientific Reports
|
December 14, 2017
Small molecules related to adrenomedullin reduce tumor burden in a mouse model of colitis-associated colon cancer
Laura Ochoa-Callejero, Josune García-Sanmartín, Sonia Martínez-Herrero, et al.
Plos One
|
January 18, 2013
Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model
Laura Ochoa-Callejero, Laura Pérez-Martínez, Susana Rubio-Mediavilla, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
February 9, 2018
Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet
Laura Pérez-Martínez, Laura Ochoa-Callejero, Susana Rubio-Mediavilla, et al.
Cancers
|
March 13, 2024
Expression of Mitochondrial Long Non-Coding RNAs, MDL1 and MDL1AS, Are Good Prognostic and/or Diagnostic Biomarkers for Several Cancers, Including Colorectal Cancer
Pablo Garrido, Adrián Casas-Benito, Ignacio M Larrayoz, et al.
Plos One
|
January 10, 2024
Role of maraviroc and/or rapamycin in the liver of IL10 KO mice with frailty syndrome
Laura Pérez-Martínez, Lourdes Romero, Eva M Verdugo-Sivianes, et al.
Aging
|
May 1, 2020
Implications of maraviroc and/or rapamycin in a mouse model of fragility
Laura Pérez-Martínez, Lourdes Romero, Sandra Muñoz-Galván, et al.
The Journal of Antimicrobial Chemotherapy
|
March 22, 2014
Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)
Laura Pérez-Martínez, Patricia Pérez-Matute, Javier Aguilera-Lizarraga, et al.
Page
of 2